Ketanest-S

Esketamine, the active ingredient in Ketanest‑S, is a NMDA receptor antagonist presented as an injectable solution for intravenous or intramuscular use. It is employed to produce dissociative anesthesia and analgesia during surgical procedures and other interventions requiring rapid onset of unconsciousness.

GNH USA supplies Ketanest‑S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Esketamine is used in clinical practice for anesthesia and sedation by targeting the NMDA receptor pathway.

- Induction of general anesthesia: Provides rapid onset of unconsciousness for surgical procedures. - Procedural sedation: Allows controlled sedation for diagnostic or minor therapeutic interventions. - Analgesia: Delivers potent pain relief during and after operative procedures.

Esketamine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Elevated blood pressure: transient increase during induction. - Tachycardia: rapid heart rate observed shortly after dosing. - Nausea or vomiting: gastrointestinal discomfort common post‑procedure. - Emergence phenomena: vivid dreams, hallucinations, or confusion during recovery.

Serious or Rare Side Effects: - Respiratory depression: severe reduction in breathing requiring support. - Laryngospasm: sudden closure of the vocal cords potentially compromising airway. - Neuropsychiatric events: persistent psychosis or severe agitation.

When using Ketanest‑S, clinicians should observe specific safety measures to minimize risks.

- Patient assessment: evaluate cardiovascular status before administration. - Monitoring: continuously observe blood pressure, heart rate, and oxygen saturation. - Airway management: be prepared for airway support and ventilation. - Drug interactions: avoid concurrent use with other central nervous system depressants. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Esketamine can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Opioids: additive respiratory depression and sedation. - Benzodiazepines: enhanced central nervous system depression. - MAO inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Sympathomimetic agents: possible exaggerated cardiovascular response. - Antihypertensives: may counteract blood pressure elevation. - CYP2B6 inhibitors: may increase esketamine plasma levels.